Liang, Xiaoyu http://orcid.org/0000-0001-7796-2441
Justice, Amy C. http://orcid.org/0000-0003-0139-5502
So-Armah, Kaku
Krystal, John H.
Sinha, Rajita
Xu, Ke
Article History
Received: 25 August 2019
Revised: 20 December 2019
Accepted: 28 January 2020
First Online: 7 February 2020
Compliance with ethical standards
:
: The authors (except JHK) declare no conflict of interest. The following competing interests for JHK: Consultant: note: the Individual Consultant Agreements listed below are less than $10,000 per year: AstraZeneca Pharmaceuticals; Biogen, Idec, MA; Biomedisyn Corporation; Bionomics, Limited (Australia); Boehringer Ingelheim International; Concert Pharmaceuticals, Inc.; Epiodyne, Inc.; Heptares Therapeutics, Limited (UK); Janssen Research & Development; L.E.K. Consulting; Otsuka America Pharmaceutical, Inc.; Perception Neuroscience Holdings, Inc.; Spring Care, Inc.; Sunovion Pharmaceuticals, Inc.; Takeda Industries; Taisho Pharmaceutical Co., Ltd. Scientific Advisory Board: Bioasis Technologies, Inc.; Biohaven Pharmaceuticals; BioXcel Therapeutics, Inc. (Clinical Advisory Board); Cadent Therapeutics (Clinical Advisory Board); PsychoGenics, Inc.; Stanley Center for Psychiatric research at the Broad Institute of MIT and Harvard; Lohocla Research Corporation. Stock: ArRETT Neuroscience, Inc.; Biohaven Pharmaceuticals; Sage Pharmaceuticals; Spring Care, Inc. Stock Options: Biohaven Pharmaceuticals Medical Sciences; BlackThorn Therapeutics, Inc.; Storm Biosciences, Inc. Income Greater than $10,000. Editorial Board: Editor—Biological Psychiatry. Patents and Inventions: (1) Seibyl JP, JHK, Charney DS. Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia. US Patent #:5,447,948.September 5, 1995; (2) Vladimir, Coric, JHK, Sanacora, Gerard—Glutamate Modulating Agents in the Treatment of Mental Disorders US Patent No. 8,778,979 B2 Patent Issue Date: July 15, 2014. US Patent Application No. 15/695,164: Filing Date: 09/05/2017; (3) Charney D, JHK, Manji H, Matthew S, Zarate C.,—Intranasal Administration of Ketamine to Treat Depression United States Application No. 14/197,767 filed on March 5, 2014; United States application or Patent Cooperation Treaty (PCT) International application No. 14/306,382 filed on June 17, 2014; (4) Zarate, C, Charney, DS, Manji, HK, Mathew, Sanjay J, JHK, Department of Veterans Affairs “Methods for Treating Suicidal Ideation”, Patent Application No. 14/197.767 filed on March 5, 2014 by Yale University Office of Cooperative Research (5) Arias A, Petrakis I, JHK—Composition and methods to treat addiction. Provisional Use Patent Application no.61/973/961. April 2, 2014. Filed by Yale University Office of Cooperative Research; (6) Chekroud, A., Gueorguieva, R., & JHK. “Treatment Selection for Major Depressive Disorder” [filing date 3rd June 2016, USPTO docket number Y0087.70116US00]. Provisional patent submission by Yale University; (7) Gihyun, Yoon, Petrakis I, JHK—Compounds, Compositions and Methods for Treating or Preventing Depression and Other Diseases. U. S. Provisional Patent Application No. 62/444,552, filed on January10, 2017 by Yale University Office of Cooperative Research OCR 7088 US01; (8) Abdallah, C, JHK, Duman, R, Sanacora, G. Combination Therapy for Treating or Preventing Depression or Other Mood Diseases. U.S. Provisional Patent Application No. 047162-7177P1 (00754) filed on August 20, 2018 by Yale University Office of Cooperative Research OCR 7451 US01. NON-Federal Research Support: AstraZeneca Pharmaceuticals provides the drug, Saracatinib, for research related to NIAAA grant “Center for Translational Neuroscience of Alcoholism [CTNA-4].